Award details

Realising the potential of a safe and protective universal vaccine for African horse sickness disease

Reference	BB/R005567/1
Principal Investigator / Supervisor	Professor Polly Roy
Co-Investigators / Co-Supervisors
Institution	London Sch of Hygiene and Trop Medicine
Department	Department of Pathogen Molecular Biology
Funding type	Research
Value (£)	237,334
Status	Completed
Type	Research Grant
Start date	01/08/2018
End date	31/01/2021
Duration	30 months

Abstract

unavailable

Summary

African horse sickness is a devastating viral disease of horses with a ~90% mortality rate. AHSV and Bluetongue Virus, BTV, that affects livestock, are closely related and spread by the same Culicoides vectors, prevalent in UK & Europe. Currently available vaccines against AHSV are neither safe nor effective and a safe vaccine that protects against all AHSV serotypes is desirable. Enabled by BBSRC funding we have designed novel vaccine candidates for all nine AHSV serotypes which are strictly replication-deficient in normal cells or animal hosts and demonstrated their suitability in ponies. To investigate their potential for commercialisation, we will investigate the duration of protection in ponies; develop a unique universal vaccine for all serotypes; define the immune response and those that are responsible for cross-protection; and develop a DIVA vaccine strain. Our data will support a broadly protective vaccine with easy production and good shelf life for protection against AHSV

Committee	Not funded via Committee
Research Topics	Animal Health, Immunology, Microbiology
Research Priority	X – Research Priority information not available
Research Initiative	Follow-On Fund Super (SuperFOF) [2012-2015]
Funding Scheme	X – not Funded via a specific Funding Scheme

I accept the terms and conditions of use (opens in new window)

export PDF file

back to list new search